Abstract：【Objective】To explore the effects of dexmedetomidine (Dex) combined with ultrasound-guided nerve block anesthesia on diabetic foot gangrene surgery. 【Methods】Eighty patients undergoing diabetic foot gangrene surgery were randomly divided into two groups, with 40 patients in each. The control group underwent ultrasound-guided nerve block anesthesia, while the observation group received anesthesia with Dex combined on the basis of the control group. The sensory and motor nerve block time of the two groups was compared, along with hemodynamic changes [heart rate (HR), blood oxygen saturation (SpO2)] at different time points before and after anesthesia. Serum immune function indicators [CD4+, CD8+, CD4+/CD8+] before anesthesia and after surgery were measured, and the incidence of adverse reactions was recorded as well. 【Results】The onset and completion time of sensory and motor blockade in the observation group were shorter than those in the control group (P<0.05); the duration of sensory and motor blockade in the observation group was longer than that in the control group (P<0.05). The HR after anesthesia in the observation group was significantly higher than that in the control group (P<0.05); the HR at the start of surgery in the observation group was lower than after anesthesia in the same group (P<0.05); the HR after anesthesia in the control group was significantly lower than before anesthesia in the same group (P<0.05). The levels of CD4+ and CD4+/CD8+ after surgery in the control group were significantly lower than before anesthesia in the same group (P<0.05); the levels of CD4+ and CD4+/CD8+ after surgery in the observation group were significantly higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The use of Dex combined with ultrasound-guided nerve block anesthesia for diabetic foot gangrene surgery significantly improves the anesthetic effect, effectively prolongs the nerve block time, maintains stable hemodynamic levels, and does not increase adverse reactions.
2023, Vol. 40 
